Ultragenyx Pharmaceutical Inc. settled a suit with the US government for $6 million over allegations it violated the False Claims Act when it paid for free genetic tests that induced prescriptions of the drug Crysvita, which would be reimbursed by Medicare or Medicaid.

Crysvita is used to treat X-linked hypophosphatemia, a rare genetic disorder characterized by low phosphate blood levels that can lead to weak bones. A genetic test is required to confirm the diagnosis and for insurers, including Medicare and Medicaid, to pay for the drug prescription.

• According to the settlement agreement filed Thursday in the US District Court ...

Learn more about Bloomberg Law or Log In to keep reading:

Learn About Bloomberg Law

AI-powered legal analytics, workflow tools and premium legal & business news.

Already a subscriber?

Log in to keep reading or access research tools.

Read Full Story: https://news.google.com/rss/articles/CBMiY2h0dHBzOi8vbmV3cy5ibG9vbWJlcmdsYXcu...